Melatonin and Cisplatin Co-Treatment Against Cancer: A Mechanistic Review of Their Synergistic Effects and Melatonin's Protective Actions Publisher Pubmed



Rafiyan M^{1, 2} ; Davoodvandi A^{2, 3} ; Reiter RJ⁴ ; Mansournia MA⁵ ; Rasooli Manesh SM⁶ ; Arabshahi V⁷ ; Asemi Z⁷
Source: Pathology Research and Practice Published:2024

Abstract

Combination chemotherapy appears to be a preferable option for some cancer patients, especially when the medications target multiple pathways of oncogenesis; individuals treated with combination treatments may have a better prognosis than those treated with single agent chemotherapy. However, research has revealed that this is not always the case, and that this technique may just enhance toxicity while having little effect on boosting the anticancer effects of the medications. Cisplatin (CDDP) is a chemotherapeutic medicine that is commonly used to treat many forms of cancer. However, it has major adverse effects such as cardiotoxicity, skin necrosis, testicular toxicity, and nephrotoxicity. Many research have been conducted to investigate the effectiveness of melatonin (MLT) as an anticancer medication. MLT operates in a variety of ways, including decreasing cancer cell growth, causing apoptosis, and preventing metastasis. We review the literature on the role of MLT as an adjuvant in CDDP-based chemotherapies and discuss how MLT may enhance CDDP's antitumor effects (e.g., by inducing apoptosis and suppressing metastasis) while protecting other organs from its adverse effects, such as cardio- and nephrotoxicity. © 2023 Elsevier GmbH